- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01849796
Transcranial Stimulation (tDCS) For the Treatment of Neuropathic Facial Pain (TDCS)
December 9, 2015 updated by: Beth Israel Medical Center
Transcranial Stimulation (TDCS) For The Treatment of Neuropathic Facial Pain.
A study to determine if transcranial direct current stimulation (tDCS, the device that regulates brain activity, can improve pain in people with neuropathic facial pain and compare which modality (inhibitory tDCS over the somatosensory cortex or excitatory tDCS over the motor cortex) can result in better pain-relief.)
Study Overview
Detailed Description
This is a pilot study designed to collect preliminary data on safety and efficacy of transcranial direct current stimulation (tDCS)to relieve pain in subjects with neuropathic facial pain,and to compare two pain-treatment tDCS modalities: inhibitory tDCS stimulation over the somatosensory cortex and excitatory tDCS over the motor cortex.
Study Type
Interventional
Enrollment (Actual)
21
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10033
- Beth Israel Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
Spontaneous facial neuropathic pain due to any of following:
- Trigeminal neuralgia, type 1, (TN1): facial pain of spontaneous onset with predominantly episodic pain.
- Trigeminal neuralgia, type 2, (TN2): facial pain of spontaneous onset with predominantly constant pain.
- Trigeminal neuropathic pain, (TNP): facial pain resulting from unintentional injury to the trigeminal system from facial trauma, oral surgery, ear, nose and throat (ENT) surgery, root injury from posterior fossa or skull base surgery, stroke, etc.
- Trigeminal deafferentation pain, (TDP): facial pain in a region of trigeminal numbness resulting from intentional injury to the trigeminal system from neurectomy, gangliolysis, rhizotomy, nucleotomy, tractotomy, or other denervating procedures.
- Symptomatic trigeminal neuralgia, (STN): facial pain resulting from multiple sclerosis.
e) Postherpetic neuralgia, (PHN): facial pain resulting from trigeminal Herpes zoster (shingles) outbreak in the trigeminal distribution.
- Pain intensity score for "worst pain in the last 24 hours" >4 on a numeric scale 0-10 at the time of enrollment and before the first stimulation of each treatment block.
- Pain intensity score for "pain right now" >4 on a numeric scale 0-10 before the first stimulation of each block of treatment.
Exclusion Criteria:
- Uncontrolled hypertension, uncontrolled diabetes, uncontrolled cardiovascular disease
- Other painful conditions than neuropathic facial pain, that are not related to and can't be distinguished from the neuropathic facial pain
- Pregnancy
- Implanted neurostimulation devices (e.g. a spinal cord stimulator, a deep brain stimulator, etc)
- Active illegal drug/alcohol abuse
- Unable to follow directions or complete tools in English.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Group A: Anodal tDCS
Group A will receive one block of real excitatory anodal tDCS over the motor cortex and one block of sham.
|
TDCS/sham will be delivered using the battery-operated device Phoresor II Auto with two saline-soaked sponge electrodes.
To deliver excitatory (anodal) tDCS over the motor cortex, the main electrode will be placed over the motor cortex on the hemisphere contralateral to the major source of pain.
The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area.
To deliver inhibitory (cathodal) tDCS, the main electrode will be placed over the somatosensory cortex on the hemisphere contralateral to the major source of pain.
The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area.
The current will be delivered at the intensity of 2mA for 20 minutes.
To deliver sham, the current will be delivered for 30 sec only to elicit tingling skin sensation but no cortical excitability changes.
|
SHAM_COMPARATOR: Arm B: Cathodal tDCS
Group B will receive one block of inhibitory cathodal tDCS over the somatosensory cortex and one block of sham.
|
TDCS/sham will be delivered using the battery-operated device Phoresor II Auto with two saline-soaked sponge electrodes.
To deliver excitatory (anodal) tDCS over the motor cortex, the main electrode will be placed over the motor cortex on the hemisphere contralateral to the major source of pain.
The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area.
To deliver inhibitory (cathodal) tDCS, the main electrode will be placed over the somatosensory cortex on the hemisphere contralateral to the major source of pain.
The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area.
The current will be delivered at the intensity of 2mA for 20 minutes.
To deliver sham, the current will be delivered for 30 sec only to elicit tingling skin sensation but no cortical excitability changes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary outcome will be a composite measure "Pain intensity/consumption of pain medication".
Time Frame: Daily from Baseline to up to 17 weeks
|
The washout period between phase I and phase II of the study is variable as patients have to go back to their baseline.
|
Daily from Baseline to up to 17 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Joy Hao, MD, Beth Israel Medical Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2010
Primary Completion (ACTUAL)
December 1, 2013
Study Completion (ACTUAL)
December 1, 2013
Study Registration Dates
First Submitted
December 27, 2012
First Submitted That Met QC Criteria
May 6, 2013
First Posted (ESTIMATE)
May 9, 2013
Study Record Updates
Last Update Posted (ESTIMATE)
December 10, 2015
Last Update Submitted That Met QC Criteria
December 9, 2015
Last Verified
December 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 148-10
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Facial Pain
-
Northwestern UniversityCompletedAtypical Facial Pain | Typical Facial PainUnited States
-
Allodynic Therapeutics, LLCWithdrawnAtypical Facial Pain | Persistent Idiopathic Facial Pain | Atypical Trigeminal Neuralgia | Neuropathic Orofacial Pain | Neuropathic Facial PainUnited States
-
University of CataniaRecruiting
-
Lithuanian University of Health SciencesUnknownPersistent Idiopathic Facial PainLithuania
-
Fayoum UniversityEnrolling by invitation
-
Pain and Analgesia Imaging and Neuroscience GroupGlaxoSmithKlineCompleted
-
David Jang, M.D.AmgenCompleted
-
University of Sao PauloCompletedAtypical Facial Pain or Atypical OdontalgiaBrazil
-
Federal University of São PauloCompletedFacial Nerve Diseases | Orofacial Pain | Peripheral Nerve Facial Nerve ParalysisBrazil
-
Cairo UniversityEnrolling by invitationBotulinum Toxin | Myofacial Pain SyndromeEgypt
Clinical Trials on tDCS
-
Hôpital le VinatierCompletedSchizophrenia | Auditory HallucinationsFrance, Tunisia
-
Universidad de AlmeriaSecretaría General de Universidades, Investigación y Tecnología, Junta de...Enrolling by invitationSubstance-Related DisordersSpain
-
Northeastern UniversityMassachusetts General Hospital; National Institute on Aging (NIA)Unknown
-
Nachum Soroker, MDUnknown
-
Bambino Gesù Hospital and Research InstituteCompleted
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)CompletedMotor Activity | Motor NeuroplasticityUnited States
-
Charite University, Berlin, GermanyCompletedMigraine With Aura | CADASIL | Cerebral Microangiopathy | ICA StenosisGermany
-
Universidade Federal de PernambucoCompleted
-
Thorsten RudroffTerminatedMultiple Sclerosis | Neuropathic PainUnited States
-
University of MichiganNational Institute of Mental Health (NIMH)Completed